Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation
Atrial fibrillation (AF) is commonly prevalent in patients with hypertrophic cardiomyopathy (HCM). However, whether the prevalence and incidence of AF are different between genotype-positive vs. genotype-negative patients with HCM remains controversial. Recent evidence has indicated that AF is often...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1023394/full |
| _version_ | 1797845593966510080 |
|---|---|
| author | Shengnan Wang He Chen Chunju Liu Mengxian Wu Wanlei Sun Shenjian Liu Yan Zheng Yan Zheng Wenfeng He Wenfeng He |
| author_facet | Shengnan Wang He Chen Chunju Liu Mengxian Wu Wanlei Sun Shenjian Liu Yan Zheng Yan Zheng Wenfeng He Wenfeng He |
| author_sort | Shengnan Wang |
| collection | DOAJ |
| description | Atrial fibrillation (AF) is commonly prevalent in patients with hypertrophic cardiomyopathy (HCM). However, whether the prevalence and incidence of AF are different between genotype-positive vs. genotype-negative patients with HCM remains controversial. Recent evidence has indicated that AF is often the first presentation of genetic HCM patients in the absence of a cardiomyopathy phenotype, implying the importance of genetic testing in this population with early-onset AF. However, the association of the identified sarcomere gene variants with HCM occurrence in the future remains unclear. How the identification of these cardiomyopathy gene variants should influence the use of anticoagulation therapy for a patient with early-onset AF is still undefined. In this review, we sought to assess the genetic variants, pathophysiological pathways, and oral anticoagulation in patients with HCM and AF. |
| first_indexed | 2024-04-09T17:41:31Z |
| format | Article |
| id | doaj.art-3b18ee182bc44b55881544c775c0cff1 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-09T17:41:31Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-3b18ee182bc44b55881544c775c0cff12023-04-17T04:26:26ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-04-011010.3389/fcvm.2023.10233941023394Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillationShengnan Wang0He Chen1Chunju Liu2Mengxian Wu3Wanlei Sun4Shenjian Liu5Yan Zheng6Yan Zheng7Wenfeng He8Wenfeng He9Department of Medical Genetics, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment ofClinical Laboratory, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, ChinaDepartment ofClinical Laboratory, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, ChinaDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Medical Genetics, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Medical Genetics, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaAtrial fibrillation (AF) is commonly prevalent in patients with hypertrophic cardiomyopathy (HCM). However, whether the prevalence and incidence of AF are different between genotype-positive vs. genotype-negative patients with HCM remains controversial. Recent evidence has indicated that AF is often the first presentation of genetic HCM patients in the absence of a cardiomyopathy phenotype, implying the importance of genetic testing in this population with early-onset AF. However, the association of the identified sarcomere gene variants with HCM occurrence in the future remains unclear. How the identification of these cardiomyopathy gene variants should influence the use of anticoagulation therapy for a patient with early-onset AF is still undefined. In this review, we sought to assess the genetic variants, pathophysiological pathways, and oral anticoagulation in patients with HCM and AF.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1023394/fullatrial fibrillationhypertrophic cardiomyopathygenotypemechanismanticoagulation |
| spellingShingle | Shengnan Wang He Chen Chunju Liu Mengxian Wu Wanlei Sun Shenjian Liu Yan Zheng Yan Zheng Wenfeng He Wenfeng He Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation Frontiers in Cardiovascular Medicine atrial fibrillation hypertrophic cardiomyopathy genotype mechanism anticoagulation |
| title | Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| title_full | Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| title_fullStr | Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| title_full_unstemmed | Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| title_short | Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| title_sort | genetic variants pathophysiological pathways and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation |
| topic | atrial fibrillation hypertrophic cardiomyopathy genotype mechanism anticoagulation |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1023394/full |
| work_keys_str_mv | AT shengnanwang geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT hechen geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT chunjuliu geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT mengxianwu geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT wanleisun geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT shenjianliu geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT yanzheng geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT yanzheng geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT wenfenghe geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation AT wenfenghe geneticvariantspathophysiologicalpathwaysandoralanticoagulationinpatientswithhypertrophiccardiomyopathyandatrialfibrillation |